Abbott Laboratories is presented as a superior alternative to volatile cannabis stocks like Tilray, offering 54 consecutive years of dividend increases and expected 10% EPS growth in 2026. The company benefits from its pending $23 billion acquisition of Exact Sciences and new FDA-approved heart rhythm treatment, though it faces headwinds from FreeStyle Libre 3 product issues and flat diagnostics segment performance.

Tilray Brands, despite expanding into hemp products and alcoholic beverages beyond cannabis, continues to struggle with profitability. The company's aggressive acquisition strategy has driven revenue growth but resulted in rising share dilution and write-downs across divisions. Analysts recommend caution until the company demonstrates sustainable earnings.

The article compares two major cannabis stocks, Tilray Brands and Canopy Growth, as potential long-term investments following recent U.S. regulatory developments. While both companies have improved financial results and positioned themselves to capitalize on emerging cannabis market opportunities, the author concludes that neither is likely to be a millionaire maker due to significant regulatory uncertainty and industry challenges. However, Tilray is recommended as the better choice due to its greater operational diversification and geographic presence.

The recreational cannabis market is projected to grow from $2.24 billion in 2025 to $3.32 billion by 2030, with a CAGR of 7.8-8.2%. Growth is driven by increasing legalization, public acceptance, demand for high-THC products, and innovation in premium edibles, beverages, and vape formats. Key players are launching innovative products and pursuing strategic acquisitions to capitalize on expanding market opportunities.

The global functional food and beverage market is projected to reach $438 billion in 2026, with oral pouches and alternative caffeine delivery formats driving growth. Doseology Sciences launched caffeine-based energy pouches under its Feed That Brain brand, while Kraft Heinz introduced the HEINZ KegChup, Tilray Brands expanded spirits distribution in Illinois, Cronos Group launched Lord Jones cannabis in Israel, and USANA Health Sciences reported strong 2025 sales with positive 2026 guidance.

Tilray Pharma's European distribution subsidiary CC Pharma has signed a strategic agreement with UK-based Smartway Pharmaceuticals to expand pharmaceutical product availability across the United Kingdom. The partnership leverages Smartway's established national distribution network and CC Pharma's European supply capabilities and GMP standards to accelerate access to specialized pharmaceuticals in the UK market, estimated at nearly one billion pounds. The agreement also aims to facilitate Tilray's integration of its medical cannabis products into the British healthcare system.

Tilray Pharma's European distributor CC Pharma has entered a strategic partnership with UK-based Smartway Pharmaceuticals to expand pharmaceutical product availability across the United Kingdom. The agreement leverages Smartway's national distribution infrastructure and CC Pharma's sourcing expertise and GMP capacity to enhance parallel imports and specialty pharmaceutical supply in the ~£1 billion UK pharma market, supporting Tilray's broader European medical expansion strategy.

CC Pharma, the European pharmaceutical distribution business of Tilray Brands, has been recognized as a TOP 100 Innovator in Germany. The award acknowledges CC Pharma's innovation strategy, operational excellence, and role as a trusted partner in Germany's pharmaceutical ecosystem, serving over 13,000 pharmacies and playing a key role in medical cannabis distribution.

Tilray Brands is launching exclusive game day promotions across its craft beer tap rooms nationwide on February 8, 2026, featuring special food and beverage deals, live entertainment, and giveaways. The company's eight participating breweries are offering bundled packages combining wings, pizza, beer, and other items at promotional prices to drive foot traffic and sales during the major sporting event.

SweetWater Brewing Company, a subsidiary of Tilray Brands, announced the launch of Big Trip Double IPA, a high-ABV (9%) extension of its popular Daytrip IPA. The new brew features citrus and tropical notes and will be available in 19.2 oz and 6-pack 12 oz cans nationwide. The launch capitalizes on the growing popularity of Double IPAs in the Southeast craft beer market.

Tilray Medical announced the launch of Tilray Medical Italia, rebranding its Italian operations previously known as FL Group. The company is expanding its medical cannabis portfolio in Italy through a partnership with Molteni Farmaceutici, offering pharmaceutical-grade products authorized by the Italian Ministry of Health. This move strengthens Tilray's regulated medical cannabis platform across Europe.

President Trump's executive order to reschedule cannabis to Schedule 3 could eliminate Section 280E of the Internal Revenue Code, allowing U.S. cannabis operators to deduct business expenses for the first time. This represents the most significant federal cannabis policy shift in over 50 years. However, challenges remain including inability to list on major exchanges and lack of banking safe harbor provisions.